04-Nov-2026 13:40:01

AARTI DRUGS Q2 FY27 CONCALL: TARGETS ~10% FY27 VOLUME GROWTH & SUSTAINABLE 15%+ EBITDA MARGIN; EXPECTS 5–10% H2 VOLUME GROWTH, EARLIER ₹1,000 CR FORMULATIONS REVENUE MILESTONE & CAPACITY EXPANSION THROUGH FY29

AARTI DRUGS LTD.